216 related articles for article (PubMed ID: 21084495)
1. Characterization of antibody-mediated neutralization directed against the hypervariable region 1 of hepatitis C virus E2 glycoprotein.
Vieyres G; Dubuisson J; Patel AH
J Gen Virol; 2011 Mar; 92(Pt 3):494-506. PubMed ID: 21084495
[TBL] [Abstract][Full Text] [Related]
2. Role of the E2 Hypervariable Region (HVR1) in the Immunogenicity of a Recombinant Hepatitis C Virus Vaccine.
Law JLM; Logan M; Wong J; Kundu J; Hockman D; Landi A; Chen C; Crawford K; Wininger M; Johnson J; Mesa Prince C; Dudek E; Mehta N; Tyrrell DL; Houghton M
J Virol; 2018 Jun; 92(11):. PubMed ID: 29540595
[TBL] [Abstract][Full Text] [Related]
3. Hepatitis C Virus Escape Studies of Human Antibody AR3A Reveal a High Barrier to Resistance and Novel Insights on Viral Antibody Evasion Mechanisms.
Velázquez-Moctezuma R; Galli A; Law M; Bukh J; Prentoe J
J Virol; 2019 Feb; 93(4):. PubMed ID: 30487284
[TBL] [Abstract][Full Text] [Related]
4. A Recombinant Hepatitis C Virus Genotype 1a E1/E2 Envelope Glycoprotein Vaccine Elicits Antibodies That Differentially Neutralize Closely Related 2a Strains through Interactions of the N-Terminal Hypervariable Region 1 of E2 with Scavenger Receptor B1.
Johnson J; Freedman H; Logan M; Wong JAJ; Hockman D; Chen C; He J; Beard MR; Eyre NS; Baumert TF; Tyrrell DL; Law JLM; Houghton M
J Virol; 2019 Nov; 93(22):. PubMed ID: 31462563
[TBL] [Abstract][Full Text] [Related]
5. Human monoclonal antibodies to a novel cluster of conformational epitopes on HCV E2 with resistance to neutralization escape in a genotype 2a isolate.
Keck ZY; Xia J; Wang Y; Wang W; Krey T; Prentoe J; Carlsen T; Li AY; Patel AH; Lemon SM; Bukh J; Rey FA; Foung SK
PLoS Pathog; 2012; 8(4):e1002653. PubMed ID: 22511875
[TBL] [Abstract][Full Text] [Related]
6. Antibody Response to Hypervariable Region 1 Interferes with Broadly Neutralizing Antibodies to Hepatitis C Virus.
Keck ZY; Girard-Blanc C; Wang W; Lau P; Zuiani A; Rey FA; Krey T; Diamond MS; Foung SK
J Virol; 2016 Jan; 90(6):3112-22. PubMed ID: 26739044
[TBL] [Abstract][Full Text] [Related]
7. Applying antibody-sensitive hypervariable region 1-deleted hepatitis C virus to the study of escape pathways of neutralizing human monoclonal antibody AR5A.
Velázquez-Moctezuma R; Law M; Bukh J; Prentoe J
PLoS Pathog; 2017 Feb; 13(2):e1006214. PubMed ID: 28231271
[TBL] [Abstract][Full Text] [Related]
8. Hypervariable region 1 differentially impacts viability of hepatitis C virus strains of genotypes 1 to 6 and impairs virus neutralization.
Prentoe J; Jensen TB; Meuleman P; Serre SB; Scheel TK; Leroux-Roels G; Gottwein JM; Bukh J
J Virol; 2011 Mar; 85(5):2224-34. PubMed ID: 21123377
[TBL] [Abstract][Full Text] [Related]
9. Hypervariable region 1 shielding of hepatitis C virus is a main contributor to genotypic differences in neutralization sensitivity.
Prentoe J; Velázquez-Moctezuma R; Foung SK; Law M; Bukh J
Hepatology; 2016 Dec; 64(6):1881-1892. PubMed ID: 27351277
[TBL] [Abstract][Full Text] [Related]
10. Monoclonal Antibodies Directed toward the Hepatitis C Virus Glycoprotein E2 Detect Antigenic Differences Modulated by the N-Terminal Hypervariable Region 1 (HVR1), HVR2, and Intergenotypic Variable Region.
Alhammad Y; Gu J; Boo I; Harrison D; McCaffrey K; Vietheer PT; Edwards S; Quinn C; Coulibaly F; Poumbourios P; Drummer HE
J Virol; 2015 Dec; 89(24):12245-61. PubMed ID: 26378182
[TBL] [Abstract][Full Text] [Related]
11. New neutralizing antibody epitopes in hepatitis C virus envelope glycoproteins are revealed by dissecting peptide recognition profiles.
Kachko A; Kochneva G; Sivolobova G; Grazhdantseva A; Lupan T; Zubkova I; Wells F; Merchlinsky M; Williams O; Watanabe H; Ivanova A; Shvalov A; Loktev V; Netesov S; Major ME
Vaccine; 2011 Dec; 30(1):69-77. PubMed ID: 22041300
[TBL] [Abstract][Full Text] [Related]
12. Role of HVR1 sequence similarity in the cross-genotypic neutralization of HCV.
Mosa AI; AbouHaidar MG; Urbanowicz RA; Tavis JE; Ball JK; Feld JJ
Virol J; 2020 Sep; 17(1):140. PubMed ID: 32948191
[TBL] [Abstract][Full Text] [Related]
13. Neutralizing monoclonal antibodies against hepatitis C virus E2 protein bind discontinuous epitopes and inhibit infection at a postattachment step.
Sabo MC; Luca VC; Prentoe J; Hopcraft SE; Blight KJ; Yi M; Lemon SM; Ball JK; Bukh J; Evans MJ; Fremont DH; Diamond MS
J Virol; 2011 Jul; 85(14):7005-19. PubMed ID: 21543495
[TBL] [Abstract][Full Text] [Related]
14. Keyhole Limpet Hemocyanin-Conjugated Peptides from Hepatitis C Virus Glycoproteins Elicit Neutralizing Antibodies in BALB/c Mice.
Deng K; Xu Z; Chen M; Liu X
J Immunol Res; 2021; 2021():3108157. PubMed ID: 33532506
[TBL] [Abstract][Full Text] [Related]
15. Fine mapping of murine antibody responses to immunization with a novel soluble form of hepatitis C virus envelope glycoprotein complex.
Ruwona TB; Giang E; Nieusma T; Law M
J Virol; 2014 Sep; 88(18):10459-71. PubMed ID: 24965471
[TBL] [Abstract][Full Text] [Related]
16. A Novel Approach To Display Structural Proteins of Hepatitis C Virus Quasispecies in Patients Reveals a Key Role of E2 HVR1 in Viral Evolution.
Tong Y; Li Q; Li R; Xu Y; Pan Y; Niu J; Zhong J
J Virol; 2020 Aug; 94(17):. PubMed ID: 32554700
[TBL] [Abstract][Full Text] [Related]
17. Murine antibodies against E2 and hypervariable region 1 cross-reactively capture hepatitis C virus.
Esumi M; Ahmed M; Zhou YH; Takahashi H; Shikata T
Virology; 1998 Nov; 251(1):158-64. PubMed ID: 9813211
[TBL] [Abstract][Full Text] [Related]
18. Complement-mediated enhancement of antibody function for neutralization of pseudotype virus containing hepatitis C virus E2 chimeric glycoprotein.
Meyer K; Basu A; Przysiecki CT; Lagging LM; Di Bisceglie AM; Conley AJ; Ray R
J Virol; 2002 Mar; 76(5):2150-8. PubMed ID: 11836392
[TBL] [Abstract][Full Text] [Related]
19. [Study of neutralization antibodie induced by DNA vaccine of HCV envelope protein 2 in mice].
Shao S; Zhou H; Tong Y; Ren Y; Chen Z
Wei Sheng Yan Jiu; 2011 May; 40(3):295-8. PubMed ID: 21695897
[TBL] [Abstract][Full Text] [Related]
20. Mutations in hepatitis C virus E2 located outside the CD81 binding sites lead to escape from broadly neutralizing antibodies but compromise virus infectivity.
Keck ZY; Li SH; Xia J; von Hahn T; Balfe P; McKeating JA; Witteveldt J; Patel AH; Alter H; Rice CM; Foung SK
J Virol; 2009 Jun; 83(12):6149-60. PubMed ID: 19321602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
